ATP1B1

Summary

ATP1B1 (ATPase Na+/K+ transporting subunit beta 1, HGNC:804) is a protein-coding gene on chromosome 1q24.2, encoding Sodium/potassium-transporting ATPase subunit beta-1 (P05026). This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane.

The protein encoded by this gene belongs to the family of Na+/K+ and H+/K+ ATPases beta chain proteins, and to the subfamily of Na+/K+ -ATPases. Na+/K+ -ATPase is an integral membrane protein responsible for establishing and maintaining the electrochemical gradients of Na and K ions across the plasma membrane. These gradients are essential for osmoregulation, for sodium-coupled transport of a variety of organic and inorganic molecules, and for electrical excitability of nerve and muscle. This enzyme is composed of two subunits, a large catalytic subunit (alpha) and a smaller glycoprotein subunit (beta). The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane. The glycoprotein subunit of Na+/K+ -ATPase is encoded by multiple genes. This gene encodes a beta 1 subunit. Alternatively spliced transcript variants encoding different isoforms have been described, but their biological validity is not known.

Source: NCBI Gene 481 — RefSeq curated summary.

At a glance

• GWAS associations: 49
• Clinical variants (ClinVar): 53 total — 1 pathogenic
• Phenotypes (HPO): 4
• Druggable target: yes — 5 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001677

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:804
Approved symbol	ATP1B1
Name	ATPase Na+/K+ transporting subunit beta 1
Location	1q24.2
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000143153
Ensembl biotype	protein_coding
OMIM	182330
Entrez	481

Gene structure

Transcript identifiers

Ensembl transcripts: 21 — 15 protein_coding, 4 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000367815, ENST00000367816, ENST00000494797, ENST00000685155, ENST00000685762, ENST00000685792, ENST00000686702, ENST00000687013, ENST00000687182, ENST00000687745, ENST00000688406, ENST00000688755, ENST00000689522, ENST00000690184, ENST00000690604, ENST00000691106, ENST00000691753, ENST00000691802, ENST00000692003, ENST00000856530, ENST00000856531

RefSeq mRNA: 1 — MANE Select: NM_001677 NM_001677

CCDS: CCDS1276

Canonical transcript exons

ENST00000367815 — 6 exons

Exon	Start	End
ENSE00001193529	169130010	169130090
ENSE00001193542	169127224	169127408
ENSE00001903510	169106690	169106926
ENSE00003488651	169111370	169111498
ENSE00003709174	169131292	169132719
ENSE00003710823	169124884	169125039

Expression profiles

Bgee: expression breadth ubiquitous, 295 present calls, max score 99.99.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 119.6679 / max 2660.4599, expressed in 1788 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
6506	64.9271	1722
6505	52.6601	1719
6513	0.9537	470
6508	0.3724	153
6509	0.3645	150
6504	0.2220	105
6507	0.1680	67

Top tissues by expression

295 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
substantia nigra pars compacta	UBERON:0001965	99.99	gold quality
renal medulla	UBERON:0000362	99.98	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.98	gold quality
lateral nuclear group of thalamus	UBERON:0002736	99.98	gold quality
pons	UBERON:0000988	99.96	gold quality
choroid plexus epithelium	UBERON:0003911	99.95	gold quality
lateral globus pallidus	UBERON:0002476	99.94	gold quality
superior vestibular nucleus	UBERON:0007227	99.94	gold quality
Brodmann (1909) area 23	UBERON:0013554	99.94	gold quality
parietal lobe	UBERON:0001872	99.92	gold quality
postcentral gyrus	UBERON:0002581	99.92	gold quality
ventral tegmental area	UBERON:0002691	99.91	gold quality
inferior vagus X ganglion	UBERON:0005363	99.90	gold quality
nephron tubule	UBERON:0001231	99.89	gold quality
CA1 field of hippocampus	UBERON:0003881	99.89	gold quality
pancreatic ductal cell	CL:0002079	99.88	gold quality
entorhinal cortex	UBERON:0002728	99.88	gold quality
jejunal mucosa	UBERON:0000399	99.87	gold quality
medulla oblongata	UBERON:0001896	99.87	gold quality
middle temporal gyrus	UBERON:0002771	99.87	gold quality
nasal cavity epithelium	UBERON:0005384	99.86	gold quality
dorsal plus ventral thalamus	UBERON:0001897	99.85	gold quality
adult organism	UBERON:0007023	99.85	gold quality
subthalamic nucleus	UBERON:0001906	99.84	gold quality
occipital lobe	UBERON:0002021	99.84	gold quality
superior frontal gyrus	UBERON:0002661	99.83	gold quality
esophagus squamous epithelium	UBERON:0006920	99.82	gold quality
primary visual cortex	UBERON:0002436	99.81	gold quality
orbitofrontal cortex	UBERON:0004167	99.80	gold quality
pigmented layer of retina	UBERON:0001782	99.79	gold quality

Single-cell (SCXA)

Detected in 28 experiment(s), a significant marker in 23.

Experiment	Marker?	Max mean expression
E-HCAD-35	yes	6037.14
E-MTAB-7316	yes	2850.34
E-MTAB-5061	yes	1784.44
E-CURD-79	yes	1695.97
E-GEOD-114530	yes	1535.12
E-GEOD-124472	yes	1450.49
E-GEOD-137537	yes	1190.24
E-MTAB-6075	yes	914.45
E-MTAB-8410	yes	785.52
E-MTAB-9841	yes	677.08
E-MTAB-10662	yes	668.69
E-CURD-119	yes	67.93
E-MTAB-10287	yes	66.02
E-MTAB-6701	yes	54.37
E-CURD-114	yes	45.08

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

1 targets.

Target	Regulation
SLC8A1	Unknown

Upstream regulators (CollecTRI, top): CEBPB, NR3C1, NR3C2, NRF1, PGR, SP1, SP3, SP4

miRNA regulators (miRDB)

145 targeting ATP1B1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-9-5P	100.00	72.28	2361
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-33A-5P	99.99	68.62	1055
HSA-MIR-33B-5P	99.99	68.58	1062
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-485-3P	99.98	70.68	1585
HSA-MIR-539-3P	99.98	70.74	1616
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-507	99.97	70.11	1915
HSA-MIR-3148	99.97	75.06	6478
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-557	99.96	70.01	1640
HSA-MIR-493-5P	99.96	72.47	2382
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-101-3P	99.94	75.03	2230
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-651-3P	99.94	73.48	5177
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-552-5P	99.93	68.56	1583

Literature-anchored findings (GeneRIF, showing 40)

• Carboxy-terminus of HKalpha(2) facilitates proper folding of tHKalpha(2)/beta(1) complex allowing translocation of heterodimer to plasma membrane where potassium uptake occurs. Otherwise, alpha/beta complex is destined for degradation. (PMID:15086469)
• N-glycans linked to the beta2 subunit of the Na,K-ATPase contain apical sorting information, and the high abundance of the beta2 subunit isoform along with the absence of the beta1 subunit, is responsible for the unusual apical location of the Na,K-ATPase (PMID:16230337)
• Data show that deglycosylation in polarized hepatic cells by drugs, or by site-directed mutagenesis of the N-linked-glycosylation residues, cause the Na+/K+-ATPase beta-subunit to traffic from the native basolateral to the apical/canalicular domain. (PMID:16339171)
• these studies are indicative of a synergism between Sp1 and CREB in mediating regulation of Na-K ATPase beta1 subunit by PGRE3; while regulation occurring through PGRE1 also involves Sp1 and CREB. (PMID:16478973)
• Study identifies an interaction between Wolframin and Na+/K+ ATPase beta1 subunit in transfected Cos7 cells, and between endogenous proteins in placental, neuroblastoma and MIN6 pancreatic beta-cell lines. (PMID:17947299)
• E2A and Na/K-ATPase beta1 subunit expression in epithelial cells are regulated by interactions between these proteins. (PMID:18727914)
• Reduced expression of the Na,K-beta(1) protein is associated with oxaliplatin resistance in cancer cells. (PMID:19322565)
• Propose that kinase-dependent regulation of the Na(+)-K(+) pump occurs via glutathionylation of its beta(1) subunit (ATP1B1) at Cys46. (PMID:19542013)
• ATP1B1 may confer susceptibility to BP regulation and hypertension in this Chinese population. (PMID:19563793)
• Silencing of ATP1B1 gene can enhance the proliferation and migration capability of SGC-7901 adenocarcinoma cells. (PMID:19619434)
• Na(+)-K(+) ATPase B1 can synergize with adriamycin and reverse drug resistance in MCF7 cells. (PMID:19664334)
• Measured properties of the purified carboxy-terminal lobe suggest that the fragment is correctly folded and compatible with the proposed model of Na,K-ATPase beta1 subunit. (PMID:19694409)
• through its interaction with ATP1B1, MLC1 is involved in the control of intracellular osmotic conditions and volume regulation in astrocytes, opening new perspectives for understanding the pathological mechanisms of MLC disease. (PMID:20926452)
• Data indicate that CypB through its interaction with Na/K-beta1 might regulate maturation and trafficking of the pump through the secretory pathway. (PMID:21085665)
• Results identified that the beta1 subunit of the host Na(+)/K(+)-ATPase beta1 subunit (ATP1B1) interacts with the cytoplasmic domain of both the influenza A and B virus M2 and BM2 proteins. (PMID:21104370)
• Ouabain could up-regulate Na+, K(+)-ATPase alpha1 subunit expression and reduce beta1-subunit expression which mediated signal transduction and decreased cell-cell adhesions and induced ECV304 cell death. (PMID:21141520)
• FXYD1 raises the affinity of the human alpha1beta1 isoform of Na,K-ATPase for Na ions (PMID:21449573)
• interactions between the beta subunits of neighboring cells maintain integrity of intercellular junctions (PMID:21642423)
• examined polymorphisms in three genes (ATP1B1, RGS5 and SELE) in relation to hypertension and blood pressure in a cohort of African-Americans (PMID:21881522)
• Data show that protein kinase A (PKA) phosphorylation has a drastic impact on Na(+)/K(+)-ATPase (NKA) structure and dynamics (PMID:22433860)
• Changes were found in mRNA and protein expressions of Na(+)/K(+)-ATPase subunits in LG from term pregnant rabbits and these changes suggest a role in the pregnancy-related LG secretion changes and dry eye symptoms observed in these animals. (PMID:23009595)
• NRF-1 regulates Atp1a1 and Atp1b1 and are important in mediating the energy generation and neuronal activity. (PMID:23048038)
• A polymorphic 3’UTR element in ATP1B1 regulates alternative polyadenylation and is associated with blood pressure. (PMID:24098465)
• ATP1B1 is epigenetically silenced by promoter methylation in both renal cell carcinoma (RCC) patients’ tissues and cell lines. (PMID:24452105)
• Activities of AE1 and the sodium pump are coregulated in kidney. (PMID:25012180)
• Impaired regulation and compromised activity of ion channel proteins contribute to the pathophysiology of vascular dementia. (PMID:25152327)
• Na,K-ATPase b1-subunit is a target of the Shh signaling pathway and loss of b1-subunit expression may contribute to tumor development and progression not only in carcinoma but also in medulloblastoma, a tumor of neuronal origin. (PMID:26286140)
• Overexpression of ATP1B1 is associated with cytogenetically normal acute myeloid leukemia. (PMID:26506237)
• the ratio between FXYD5 and alpha1-beta1 heterodimer determines whether the Na,K-ATPase acts as a positive or negative regulator of intercellular adhesion. (PMID:27142834)
• Our study describes the potent inhibition of Chikungunya virus and related alphaviruses by the cardiac glycoside digoxin and demonstrates a function for the sodium-potassium ATPase in Chikungunya virus infection. (PMID:27222471)
• Expression of miR-26a and miR-29a was significantly down regulated in leukoplakia and cancer tissues but up regulated in lichen planus tissues. Expression of target genes such as, ADAMTS7, ATP1B1, COL4A2, CPEB3, CDK6, DNMT3a and PI3KR1 was significantly down regulated in at least two of three disease types with respect to normal tissues. (PMID:27515006)
• This study reports molecular dynamic simulations of the human NaK-ATPase alpha1 beta 1 isoform embedded into 1,2-oleoylphosphatidylcholine bilayer. (PMID:27966362)
• Novel Single Nucleotide Polymorphism at ATP1B1 implicate gene regulatory dysfunction in QT prolongation in African and Hispanic Americans. (PMID:27988371)
• miR-192-5p in the kidney protects against the development of hypertension, which is mediated, at least in part, by targeting Atp1b1. (PMID:30595117)
• These findings reveal that the downregulation of the Na,KATPase beta1 subunit enhances the expression of profibrotic molecules in alveolar epithelial cells and may contribute to Idiopathic pulmonary fibrosis pathogenesis. (PMID:31115510)
• Na, K-ATPase alpha1 and beta1 subunits are degraded in lysosomes by RNF183-mediated ubiquitination of beta1 subunit. (PMID:31732153)
• Na/K-ATPase beta1-subunit associates with neuronal growth regulator 1 (NEGR1) to participate in intercellular interactions. (PMID:32958118)
• The Na+, K+-ATPase beta1 subunit regulates epithelial tight junctions via MRCKalpha. (PMID:33507884)
• Inducible ATP1B1 Upregulates Antiviral Innate Immune Responses by the Ubiquitination of TRAF3 and TRAF6. (PMID:34011520)
• Hypercapnia Induces Inositol-Requiring Enzyme 1alpha-Driven Endoplasmic Reticulum-associated Degradation of the Na,K-ATPase beta-Subunit. (PMID:34192507)

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	atp1b1a	ENSDARG00000013144
danio_rerio	atp1b1b	ENSDARG00000076833
mus_musculus	Atp1b1	ENSMUSG00000026576
rattus_norvegicus	Atp1b1	ENSRNOG00000002934
drosophila_melanogaster	CG11703	FBGN0038690
drosophila_melanogaster	CG5250	FBGN0038691
caenorhabditis_elegans		WBGENE00008074

Paralogs (4): ATP1B3 (ENSG00000069849), ATP1B4 (ENSG00000101892), ATP1B2 (ENSG00000129244), ATP4B (ENSG00000186009)

Protein

Protein identifiers

Sodium/potassium-transporting ATPase subunit beta-1 — P05026 (reviewed: P05026)

Alternative names: Sodium/potassium-dependent ATPase subunit beta-1

All UniProt accessions (5): P05026, A0A8I5KNT2, A0A8I5KX89, A3KLL5, B7Z9S8

UniProt curated annotations — full annotation on UniProt →

Function. This is the non-catalytic component of the active enzyme, which catalyzes the hydrolysis of ATP coupled with the exchange of Na(+) and K(+) ions across the plasma membrane. The beta subunit regulates, through assembly of alpha/beta heterodimers, the number of sodium pumps transported to the plasma membrane. Plays a role in innate immunity by enhancing virus-triggered induction of interferons (IFNs) and interferon stimulated genes (ISGs). Mechanistically, enhances the ubiquitination of TRAF3 and TRAF6 as well as the phosphorylation of TAK1 and TBK1. Involved in cell adhesion and establishing epithelial cell polarity.

Subunit / interactions. The sodium/potassium-transporting ATPase is composed of a catalytic alpha subunit, an auxiliary non-catalytic beta subunit and an additional regulatory subunit. Interacts with catalytic subunit ATP12A. Interacts with regulatory subunit FXYD1. Interacts with regulatory subunit FXYD3. Interacts with NKAIN1, NKAIN2 and NKAIN4. Interacts with MLC1. Part of a complex containing MLC1, TRPV4, AQP4 and HEPACAM. Interacts with KIRREL3. Interacts with OBSCN (via protein kinase domain 1). Interacts with TRAF3 and TRAF6.

Subcellular location. Cell membrane. Apical cell membrane. Sarcolemma.

Tissue specificity. Found in most tissues.

Post-translational modifications. Glutathionylated. N-glycosylated.

Domain organisation. The C-terminal lobe folds into an immunoglobulin-like domain and mediates cell adhesion properties.

Similarity. Belongs to the X(+)/potassium ATPases subunit beta family.

Isoforms (2)

UniProt ID	Names	Canonical?
P05026-1	1	yes
P05026-2	2

RefSeq proteins (1): NP_001668* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000402	Na/K_ATPase_sub_beta	Family
IPR038702	Na/K_ATPase_sub_beta_sf	Homologous_superfamily

Pfam: PF00287

UniProt features (42 total): strand 14, helix 8, turn 6, disulfide bond 3, glycosylation site 3, topological domain 2, modified residue 2, chain 1, splice variant 1, transmembrane region 1, region of interest 1

Structure

Experimental structures (PDB)

11 structures.

PDB	Method	Resolution (Å)
8ZYJ	ELECTRON MICROSCOPY	2.37
9WAJ	ELECTRON MICROSCOPY	2.39
7E20	ELECTRON MICROSCOPY	2.7
9WAK	ELECTRON MICROSCOPY	2.86
7E21	ELECTRON MICROSCOPY	2.9
7E1Z	ELECTRON MICROSCOPY	3.2
8D3V	ELECTRON MICROSCOPY	3.4
8D3W	ELECTRON MICROSCOPY	3.5
8D3U	ELECTRON MICROSCOPY	3.7
8D3Y	ELECTRON MICROSCOPY	3.9
8D3X	ELECTRON MICROSCOPY	4.1

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P05026-F1	89.68	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 11, 101

Disulfide bonds (3): 126–149, 159–175, 213–276

Glycosylation sites (3): 158, 193, 265

Function

Pathways and Gene Ontology

Reactome pathways

14 pathways

ID	Pathway
R-HSA-210991	Basigin interactions
R-HSA-5578775	Ion homeostasis
R-HSA-936837	Ion transport by P-type ATPases
R-HSA-9679191	Potential therapeutics for SARS
R-HSA-109582	Hemostasis
R-HSA-1643685	Disease
R-HSA-202733	Cell surface interactions at the vascular wall
R-HSA-382551	Transport of small molecules
R-HSA-397014	Muscle contraction
R-HSA-5576891	Cardiac conduction
R-HSA-5663205	Infectious disease
R-HSA-9679506	SARS-CoV Infections
R-HSA-9824446	Viral Infection Pathways
R-HSA-983712	Ion channel transport

MSigDB gene sets: 622 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, GOBP_POTASSIUM_ION_TRANSPORT, TGGTGCT_MIR29A_MIR29B_MIR29C, GOBP_ESTABLISHMENT_OR_MAINTENANCE_OF_TRANSMEMBRANE_ELECTROCHEMICAL_GRADIENT, AP1_01, AAGCAAT_MIR137, MYOGENIN_Q6, GOBP_CIRCULATORY_SYSTEM_PROCESS, SWEET_KRAS_ONCOGENIC_SIGNATURE, GOBP_INTRACELLULAR_PROTEIN_TRANSPORT, GOBP_SODIUM_ION_TRANSMEMBRANE_TRANSPORT, GCANCTGNY_MYOD_Q6, GOZGIT_ESR1_TARGETS_DN, AAGCCAT_MIR135A_MIR135B, ACEVEDO_NORMAL_TISSUE_ADJACENT_TO_LIVER_TUMOR_DN

GO Biological Process (30): response to hypoxia (GO:0001666), intracellular calcium ion homeostasis (GO:0006874), intracellular sodium ion homeostasis (GO:0006883), cell adhesion (GO:0007155), establishment or maintenance of transmembrane electrochemical gradient (GO:0010248), regulation of gene expression (GO:0010468), regulation of cardiac muscle contraction by calcium ion signaling (GO:0010882), intracellular potassium ion homeostasis (GO:0030007), sodium ion transmembrane transport (GO:0035725), sodium ion export across plasma membrane (GO:0036376), protein transport into plasma membrane raft (GO:0044861), innate immune response (GO:0045087), ATP metabolic process (GO:0046034), protein stabilization (GO:0050821), relaxation of cardiac muscle (GO:0055119), cardiac muscle contraction (GO:0060048), protein localization to plasma membrane (GO:0072659), membrane repolarization (GO:0086009), membrane repolarization during cardiac muscle cell action potential (GO:0086013), cell communication by electrical coupling involved in cardiac conduction (GO:0086064), proton transmembrane transport (GO:1902600), regulation of calcium ion transmembrane transport (GO:1903169), positive regulation of sodium ion export across plasma membrane (GO:1903278), positive regulation of potassium ion import across plasma membrane (GO:1903288), potassium ion import across plasma membrane (GO:1990573), immune system process (GO:0002376), monoatomic ion transport (GO:0006811), potassium ion transport (GO:0006813), sodium ion transport (GO:0006814), metal ion transport (GO:0030001)

GO Molecular Function (9): ATPase activator activity (GO:0001671), P-type sodium:potassium-exchanging transporter activity (GO:0005391), protein kinase binding (GO:0019901), MHC class II protein complex binding (GO:0023026), protein-macromolecule adaptor activity (GO:0030674), protein heterodimerization activity (GO:0046982), ATPase binding (GO:0051117), transporter activator activity (GO:0141109), protein binding (GO:0005515)

GO Cellular Component (14): plasma membrane (GO:0005886), sodium:potassium-exchanging ATPase complex (GO:0005890), caveola (GO:0005901), intercalated disc (GO:0014704), membrane (GO:0016020), basolateral plasma membrane (GO:0016323), apical plasma membrane (GO:0016324), lateral plasma membrane (GO:0016328), T-tubule (GO:0030315), organelle membrane (GO:0031090), sperm flagellum (GO:0036126), sarcolemma (GO:0042383), extracellular exosome (GO:0070062), extracellular vesicle (GO:1903561)

Reactome top-level categories

Rollup of top-10 pathways:

Category	Pathways
Cell surface interactions at the vascular wall	1
Cardiac conduction	1
Ion channel transport	1
SARS-CoV Infections	1
Hemostasis	1
Muscle contraction	1
Disease	1
Viral Infection Pathways	1
Infectious disease	1
Transport of small molecules	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
intracellular monoatomic cation homeostasis	3
cellular anatomical structure	3
molecular function activator activity	2
membrane	2
plasma membrane region	2
plasma membrane	2
response to stress	1
response to decreased oxygen levels	1
calcium ion homeostasis	1
sodium ion homeostasis	1
cellular process	1
monoatomic ion transmembrane transport	1
gene expression	1
regulation of macromolecule biosynthetic process	1
calcium-mediated signaling	1
regulation of cardiac muscle contraction	1
cardiac muscle contraction	1
potassium ion homeostasis	1
sodium ion transport	1
monoatomic cation transmembrane transport	1
sodium ion transmembrane transport	1
export across plasma membrane	1
protein transport into membrane raft	1
protein localization to plasma membrane raft	1
immune response	1
defense response to symbiont	1
purine ribonucleotide metabolic process	1
purine ribonucleoside triphosphate metabolic process	1
regulation of protein stability	1
relaxation of muscle	1
striated muscle contraction	1
heart contraction	1
protein localization to membrane	1
protein localization to cell periphery	1
regulation of membrane potential	1
cardiac muscle cell action potential	1
membrane repolarization during action potential	1
cardiac muscle cell membrane repolarization	1
cell communication by electrical coupling	1
cardiac conduction	1

Protein interactions and networks

STRING

1988 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ATP1B1	ATP1A3	P13637	922
ATP1B1	NKAIN1	Q4KMZ8	911
ATP1B1	ATP1A2	P50993	876
ATP1B1	WFS1	O76024	868
ATP1B1	ATP1A1	P05023	850
ATP1B1	ATP1A4	Q13733	850
ATP1B1	FXYD2	P54710	833
ATP1B1	NME7	Q9Y5B8	832
ATP1B1	NKAIN4	Q8IVV8	821
ATP1B1	FXYD7	P58549	804
ATP1B1	NKAIN2	Q5VXU1	754
ATP1B1	ESAM	Q96AP7	746
ATP1B1	ATP1B2	P14415	690
ATP1B1	SELE	P16111	685
ATP1B1	PXK	Q7Z7A4	648

IntAct

119 interactions, top by confidence:

A	B	Type	Score
ATP1A1	ATP1B1	psi-mi:“MI:0915”(physical association)	0.910
ATP1A1	ATP1B1	psi-mi:“MI:0407”(direct interaction)	0.910
ATP1A1	ATP1B1	psi-mi:“MI:0914”(association)	0.910
ATP1B1	ATP1A1	psi-mi:“MI:0914”(association)	0.910
EGFR	GAPDH	psi-mi:“MI:0914”(association)	0.790
CD9	ADAM10	psi-mi:“MI:0914”(association)	0.750
CFTR	ESYT2	psi-mi:“MI:0914”(association)	0.710
ATP1B1	SLC4A1	psi-mi:“MI:0915”(physical association)	0.670
ATP1B1	SLC4A1	psi-mi:“MI:0914”(association)	0.670
SLC4A1	ATP1B1	psi-mi:“MI:0403”(colocalization)	0.670
SLC4A1	ATP1B1	psi-mi:“MI:0407”(direct interaction)	0.670
	PMPCB	psi-mi:“MI:0914”(association)	0.640
WFS1	ATP1B1	psi-mi:“MI:0915”(physical association)	0.580

BioGRID (206): ATP1B1 (Affinity Capture-MS), ACAA2 (Co-fractionation), ACAT1 (Co-fractionation), ATP1A1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation), ATP1B1 (Co-fractionation)

ESM2 similar proteins: A5A6J8, P05026, P05027, P05028, P05029, P06583, P07340, P08251, P13638, P14094, P14231, P14415, P18434, P18597, P18598, P21188, P30715, P30716, P33704, P33879, P43002, P50992, P51164, P51165, P51575, P51577, P54709, Q17QL5, Q202B1, Q24048, Q28030, Q2HZ96, Q4R4V5, Q5E9U1, Q5F362, Q5J583, Q5R6C0, Q5R8S8, Q6AY41, Q8L8W0

Diamond homologs: A5A6J8, A7MB71, P05026, P05027, P05028, P05029, P06583, P07340, P08251, P13638, P14094, P14231, P14415, P18434, P18597, P18598, P21188, P25169, P30715, P30716, P33704, P33879, P43002, P51165, P54709, P97370, Q202B1, Q24046, Q28030, Q2HZ96, Q3T0C6, Q4R4V5, Q5J583, Q5R8S8, Q60489, Q63377, Q8WMG3, Q99ME6, Q9BDK6, Q9GLC3

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
NR3C1	“down-regulates quantity by repression”	ATP1B1	“transcriptional regulation”
NR3C2	“down-regulates quantity by repression”	ATP1B1	“transcriptional regulation”
RNF183	“down-regulates quantity by destabilization”	ATP1B1	polyubiquitination
hsa-miR-29a-5p	“down-regulates quantity by repression”	ATP1B1	“post transcriptional regulation”
WFS1	“up-regulates quantity”	ATP1B1	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 94 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

GO biological processes:

GO term	Partners	Fold	FDR
neuron apoptotic process	5	11.0×	1e-02

Disease & clinical

Clinical variants and AI predictions

ClinVar

53 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	30
Likely benign	4
Benign	4

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
558766	Single allele	Pathogenic

SpliceAI

3002 predictions. Top by Δscore:

Variant	Effect	Δscore
1:169106925:GT:G	donor_gain	1.0000
1:169106927:G:GG	donor_gain	1.0000
1:169111366:GCA:G	acceptor_loss	1.0000
1:169111367:CA:C	acceptor_loss	1.0000
1:169111368:A:AG	acceptor_gain	1.0000
1:169111368:AGT:A	acceptor_loss	1.0000
1:169111369:G:GG	acceptor_gain	1.0000
1:169111369:G:GT	acceptor_loss	1.0000
1:169111369:GTTA:G	acceptor_gain	1.0000
1:169111369:GTTAA:G	acceptor_gain	1.0000
1:169111495:CCAG:C	donor_loss	1.0000
1:169111496:CAGG:C	donor_loss	1.0000
1:169111497:AG:A	donor_loss	1.0000
1:169111498:GGT:G	donor_loss	1.0000
1:169111499:G:A	donor_loss	1.0000
1:169111500:T:G	donor_loss	1.0000
1:169124872:T:A	acceptor_gain	1.0000
1:169124876:T:A	acceptor_gain	1.0000
1:169124877:G:A	acceptor_gain	1.0000
1:169124879:TCTAG:T	acceptor_gain	1.0000
1:169124880:CTA:C	acceptor_loss	1.0000
1:169124880:CTAGG:C	acceptor_gain	1.0000
1:169124881:TA:T	acceptor_loss	1.0000
1:169124881:TAG:T	acceptor_gain	1.0000
1:169124882:A:AG	acceptor_gain	1.0000
1:169124882:AG:A	acceptor_gain	1.0000
1:169124882:AGGAT:A	acceptor_gain	1.0000
1:169124883:G:GT	acceptor_gain	1.0000
1:169124883:GG:G	acceptor_gain	1.0000
1:169124883:GGA:G	acceptor_gain	1.0000

AlphaMissense

1994 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:169106909:G:T	R27M	1.000
1:169111384:T:C	F38L	1.000
1:169111386:C:A	F38L	1.000
1:169111386:C:G	F38L	1.000
1:169111405:T:C	C45R	1.000
1:169111409:T:C	L46P	1.000
1:169111427:G:A	G52E	1.000
1:169127286:T:A	C149S	1.000
1:169127287:G:C	C149S	1.000
1:169130079:T:A	C213S	1.000
1:169130079:T:C	C213R	1.000
1:169130080:G:C	C213S	1.000
1:169131469:T:A	C276S	1.000
1:169131469:T:C	C276R	1.000
1:169131470:G:C	C276S	1.000
1:169131524:G:C	R294P	1.000
1:169106909:G:C	R27T	0.999
1:169106910:G:C	R27S	0.999
1:169106910:G:T	R27S	0.999
1:169106923:T:A	W32R	0.999
1:169106923:T:C	W32R	0.999
1:169111394:T:A	I41K	0.999
1:169111402:G:C	G44R	0.999
1:169111403:G:A	G44D	0.999
1:169111409:T:A	L46Q	0.999
1:169111411:G:C	A47P	0.999
1:169111412:C:A	A47D	0.999
1:169111414:G:C	G48R	0.999
1:169111415:G:A	G48D	0.999
1:169111420:T:C	F50L	0.999

dbSNP variants (sampled 300 via entrez): RS1000003322 (1:169115208 AGGGGGGT>A), RS1000131391 (1:169118895 A>C), RS1000176887 (1:169109713 G>A), RS1000430440 (1:169107149 G>A), RS1000574431 (1:169124094 C>A,T), RS1000610836 (1:169132181 C>T), RS1000622234 (1:169132573 A>G), RS1000630659 (1:169130744 T>C), RS1000682994 (1:169130495 A>G), RS1000766217 (1:169105291 G>A,T), RS1000824012 (1:169106177 C>G,T), RS1001028472 (1:169123758 C>A,T), RS1001081082 (1:169117809 G>A), RS1001084472 (1:169108483 TCTC>T), RS1001126058 (1:169126593 C>T)

Disease associations

OMIM: gene MIM:182330 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): cardiac rhythm disease (MONDO:0007263)

Orphanet (0):

HPO phenotypes

4 total (4 of 4 shown, HPO-id order):

HPO	Term
HP:0001426	Non-Mendelian inheritance
HP:0004421	Elevated systolic blood pressure
HP:0004972	Elevated mean arterial pressure
HP:0005117	Elevated diastolic blood pressure

GWAS associations

49 associations (top):

Study	Trait	p-value
GCST000364_2	QT interval	1.000000e-15
GCST001746_16	QT interval	2.000000e-10
GCST002500_10	QT interval	4.000000e-17
GCST002500_11	QT interval	3.000000e-21
GCST002500_12	QT interval	1.000000e-31
GCST002500_26	QT interval	1.000000e-10
GCST002500_27	QT interval	1.000000e-15
GCST002542_1	Electrocardiographic traits	1.000000e-06
GCST002616_19	Mitochondrial DNA levels	8.000000e-06
GCST004217_2	Fuchs’s corneal dystrophy	1.000000e-18
GCST005171_20	QT interval	9.000000e-18
GCST005171_59	QT interval	3.000000e-15
GCST005171_60	QT interval	7.000000e-15
GCST005195_136	Coronary artery disease	3.000000e-12
GCST005196_190	Coronary artery disease	4.000000e-13
GCST005790_81	Rosacea symptom severity	6.000000e-06
GCST010796_2834	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-08
GCST010796_2835	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-10
GCST010796_2836	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-09
GCST010796_2837	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-11
GCST010796_2838	Electrocardiogram morphology (amplitude at temporal datapoints)	6.000000e-12
GCST010796_2839	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-13
GCST010796_2840	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-13
GCST010796_2841	Electrocardiogram morphology (amplitude at temporal datapoints)	5.000000e-13
GCST010796_2842	Electrocardiogram morphology (amplitude at temporal datapoints)	4.000000e-12
GCST010796_2843	Electrocardiogram morphology (amplitude at temporal datapoints)	8.000000e-14
GCST010796_2844	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-12
GCST010796_2845	Electrocardiogram morphology (amplitude at temporal datapoints)	3.000000e-12
GCST010796_2846	Electrocardiogram morphology (amplitude at temporal datapoints)	1.000000e-14
GCST010796_2847	Electrocardiogram morphology (amplitude at temporal datapoints)	2.000000e-15

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004682	QT interval
EFO:0006312	mitochondrial DNA measurement
EFO:0009180	rosacea severity measurement
EFO:0004327	electrocardiography

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (4): CHEMBL2095186 (PROTEIN COMPLEX GROUP), CHEMBL2379 (SINGLE PROTEIN), CHEMBL6066559 (PROTEIN COMPLEX), CHEMBL6066560 (PROTEIN COMPLEX)

Molecules with ChEMBL bioactivity

5 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 160,774 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1503	OMEPRAZOLE	4	52,284
CHEMBL1751	DIGOXIN	4	67,342
CHEMBL254219	DIGITOXIN	4	16,757
CHEMBL480	LANSOPRAZOLE	4	24,317
CHEMBL2068971	ROSTAFUROXIN	2	74

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: transporter — Na⁺/K⁺-ATPases

Binding affinities (BindingDB)

16 measured of 18 human assays (18 total across all organisms); most potent 16 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value
DEt (12)	KI	53 nM
DEtDA (10)	KI	69 nM
DbisGly (14)	KI	80 nM
DMe (11)	KI	101 nM
DSCar (8)	KI	102 nM
DGly (2)	KI	124 nM
CS337	KI	139 nM
DGlyN (4)	KI	152 nM
Dbis	KI	196 nM
DMeCF3 (13)	KI	199 nM
DAlaN (5)	KI	232 nM
DSerN (7)	KI	242 nM
DPrN (9)	KI	249 nM
DOH (1)	KI	311 nM
DSer (6)	KI	316 nM
DGlMe (3)	KI	540 nM

ChEMBL bioactivities

267 potent at pChembl≥5 of 320 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.52	IC50	3	nM	CHEMBL2092909
8.38	Ki	4.2	nM	CHEMBL5765464
8.32	IC50	4.79	nM	CHEMBL1651648
8.27	Ki	5.4	nM	CHEMBL5879229
8.17	IC50	6.79	nM	CHEMBL1651648
8.15	IC50	7	nM	CHEMBL2092738
8.15	IC50	7.04	nM	CHEMBL1651624
8.10	IC50	8	nM	CHEMBL3085467
8.10	IC50	8	nM	CHEMBL3085497
8.10	Ki	8	nM	CHEMBL5879229
8.10	IC50	8	nM	DIGITOXIGENIN
8.10	IC50	8	nM	DIGITOXIN
8.07	Ki	8.6	nM	CHEMBL5876237
8.05	IC50	9	nM	CHEMBL3085468
8.00	Ki	10.1	nM	CHEMBL5832044
7.98	IC50	10.5	nM	CHEMBL3349024
7.97	IC50	10.7	nM	CHEMBL3350144
7.92	IC50	12	nM	CHEMBL2069010
7.84	Ki	14.6	nM	CHEMBL6056661
7.84	Ki	14.3	nM	CHEMBL6026321
7.82	Ki	15.2	nM	CHEMBL5910596
7.82	Ki	15.3	nM	CHEMBL5768226
7.80	IC50	16	nM	CHEMBL2068887
7.80	IC50	16	nM	CHEMBL3349024
7.75	IC50	17.8	nM	CHEMBL1159613
7.74	Ki	18.3	nM	CHEMBL5765464
7.74	Ki	18.3	nM	CHEMBL5957388
7.70	IC50	20	nM	DIGITOXIGENIN
7.70	IC50	20	nM	CHEMBL2068894
7.70	IC50	20	nM	CHEMBL2068887
7.69	Ki	20.6	nM	CHEMBL5748673
7.67	Ki	21.6	nM	CHEMBL5780414
7.66	IC50	22	nM	BUFALIN
7.63	Ki	23.2	nM	CHEMBL6031986
7.61	Ki	24.3	nM	CHEMBL5851200
7.60	IC50	25	nM	CHEMBL2068888
7.60	Ki	25	nM	CHEMBL5765464
7.55	IC50	28.2	nM	CHEMBL3350144
7.54	Ki	28.9	nM	CHEMBL5791351
7.54	Ki	28.6	nM	CHEMBL6030183
7.53	Ki	29.5	nM	DIGITOXIN
7.52	IC50	30	nM	CHEMBL2068896
7.52	IC50	30	nM	CHEMBL2068909
7.51	Ki	30.7	nM	CHEMBL5879229
7.50	Ki	31.6	nM	CHEMBL5876237
7.48	Ki	33.4	nM	CHEMBL5961305
7.47	Kd	33.47	nM	CHEMBL5653589
7.47	ED50	33.47	nM	CHEMBL5653589
7.41	Ki	38.9	nM	CHEMBL5814784
7.41	IC50	38.9	nM	CHEMBL3349024

PubChem BioAssay actives

248 with measured affinity, of 413 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
3-[(3S,8R,9S,10S,13R,14R,17S)-14-hydroxy-10,13-dimethyl-3-[[(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0030	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0048	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0070	uM
3-[(3S,8R,9S,10S,13R,14R,17R)-14-hydroxy-10,13-dimethyl-3-[[(2R,3S,4S,5R,6S)-3,4,5,6-tetrahydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0070	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0080	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0080	uM
3-[(3S,5S,8R,9S,10S,13R,14R,17R)-3-[[(2S,3R,4R,6S)-3,4-dihydroxy-6-[[(2S,3R,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methoxy]oxan-2-yl]methoxy]-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0080	uM
3-[(3S,5S,8R,9S,10S,13R,14R,17R)-3-[[(2S,3R,4R,6S)-6-[[(2S,3R,4R,6S)-3,4-dihydroxy-6-[[(2S,3R,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methoxy]oxan-2-yl]methoxy]-3,4-dihydroxyoxan-2-yl]methoxy]-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0080	uM
3-[(3S,5S,8R,9S,10S,13R,14R,17R)-14-hydroxy-10,13-dimethyl-3-[[(2S,3R,4R,6S)-3,4,6-trihydroxyoxan-2-yl]methoxy]-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0090	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0105	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2R,3S,4S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0107	uM
(2R,4S,5R)-2-[[(3S,5R,8R,9S,10S,13R,14S,17S)-14-hydroxy-10,13-dimethyl-17-(nitromethyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0120	uM
3-[(3S,10S,12S,13S,14S,17R)-3-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-[(2,4-dimethyl-1,4-oxazepan-7-yl)oxy]-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0156	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-(2-aminoethoxyimino)prop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146853: 50% displacement of the specific [3H]ouabain binding from the dog kidney Na+/K+ ATPase	ic50	0.0160	uM
3-[(3S,10S,12S,13S,14S,17R)-3-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-[[4-(2-aminoethyl)-2-methyl-1,4-oxazepan-7-yl]oxy]-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0167	uM
3-[(13R)-14-hydroxy-10,13-dimethyl-3-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0178	uM
3-[(3S,10S,12S,13S,14S,17R)-3-[(2R,4S,5S,6S)-5-[(2S,4S,5S,6S)-5-[(4-ethyl-2-methyl-1,4-oxazepan-7-yl)oxy]-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0185	uM
[7-[(2S,3S,4S,6S)-6-[(2S,3S,4S,6R)-6-[[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-1,4-oxazepan-4-yl]urea	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0200	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(E)-3-aminopropoxyiminomethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;oxalic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0200	uM
2-[7-[(2S,3S,4S,6S)-6-[(2S,3S,4S,6R)-6-[[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-1,4-oxazepan-4-yl]acetamide	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0204	uM
5-[(3S,5R,8R,9S,10S,13R,14S,17R)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]pyran-2-one	1941870: Inhibition of NA+/K+ ATPase (unknown origin) activity	ic50	0.0220	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-[2-(dimethylamino)ethoxyimino]prop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146853: 50% displacement of the specific [3H]ouabain binding from the dog kidney Na+/K+ ATPase	ic50	0.0250	uM
2-[7-[(2S,3S,4S,6S)-6-[(2S,3S,4S,6R)-6-[[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-1,4-oxazepan-4-yl]acetic acid	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0250	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-[2-(dimethylamino)ethoxyimino]prop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;oxalic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0300	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-(2-aminoethoxyimino)-2-methylprop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol;(E)-but-2-enedioic acid	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0300	uM
4-methyl-3-[(2-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147907: Binding affinity to human ATP1B1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0335	uM
3-[7-[(2S,3S,4S,6S)-6-[(2S,3S,4S,6R)-6-[[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-1,4-oxazepan-4-yl]pentanedioic acid	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0349	uM
(2R,4bS,7S,8aR)-2-[(1E,3S)-1-(2-aminoethoxyimino)pentan-3-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.0400	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(E)-2-(dimethylamino)ethoxyiminomethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146853: 50% displacement of the specific [3H]ouabain binding from the dog kidney Na+/K+ ATPase	ic50	0.0400	uM
3-[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-3-[(2R,4S,5S,6S)-4-hydroxy-5-[(2S,4S,5S,6S)-4-hydroxy-6-methyl-5-[[2-methyl-4-(2,2,2-trifluoroethyl)-1,4-oxazepan-7-yl]oxy]oxan-2-yl]oxy-6-methyloxan-2-yl]oxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0440	uM
(2R,4S,5R)-2-[[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-17-(2-nitroethyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0450	uM
3-[7-[(2S,3S,4S,6S)-6-[(2S,3S,4S,6R)-6-[[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-1,4-oxazepan-4-yl]propanamide	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0470	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(2E)-2-(2-aminoethoxyimino)ethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.0500	uM
4-methyl-3-[(1-methyl-6-pyridin-3-ylpyrazolo[3,4-d]pyrimidin-4-yl)amino]-N-[3-(trifluoromethyl)phenyl]benzamide	2147907: Binding affinity to human ATP1B1 incubated for 45 mins by Kinobead based pull down assay	kd	0.0536	uM
Digoxin	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0550	uM
(E)-but-2-enedioic acid;(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(E,3E)-3-[2-(dimethylamino)ethoxyimino]-2-methylprop-1-enyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0600	uM
6-[[(3S,8R,9S,10S,13R,14R,17S)-14-hydroxy-17-[(1S)-1-hydroxyethyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-(hydroxymethyl)oxane-3,4-diol	146854: Compound is evaluated for inhibition of specific binding of [3H]ouabain to membranes from dog heart	ic50	0.0600	uM
2-[7-[(2S,3S,4S,6S)-6-[(2S,3S,4S,6R)-6-[[(3S,10S,12S,13S,14S,17R)-12,14-dihydroxy-10,13-dimethyl-17-(5-oxo-2H-furan-3-yl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyl-1,4-oxazepan-4-yl]propanamide	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0670	uM
3-[(5R,8R,9S,10S,13R,14R,17R)-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0700	uM
3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0740	uM
(2R,3R,4R,5R,6R)-6-[[(3R)-14-hydroxy-17-(1-hydroxyethyl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxymethyl]oxane-2,3,4,5-tetrol	49025: Inhibition of [3H]ouabain binding to Na/K ATP-ase in dog heart muscle	ic50	0.0750	uM
(3S,5R,8R,9S,10S,13R,14S,17R)-17-[(1E,3E)-6-aminohexa-1,3-dienyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0800	uM
(3S,5R,8R,9S,10S,13R,14S,17S)-17-[(3Z)-3-(2-aminoethoxyimino)propyl]-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthrene-3,14-diol	146858: In vitro inhibitory concentration against dog kidney Na+/K+ ATPase	ic50	0.0800	uM
3-[(3S,5R,8R,9S,10S,13R,14S,17R)-14-hydroxy-10,13-dimethyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	146845: Inhibition of hog kidney Na+, K+-dependent ATPase	ic50	0.0870	uM
(3S,4R,6R)-6-[[(3S,5R,8R,9S,10S,13R,14S,17S)-14-hydroxy-10,13-dimethyl-17-(nitromethyl)-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-2-methyloxane-3,4-diol	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0880	uM
3-[(1R,3S,5S,8R,9S,10R,11R,13R,14S,17R)-1,5,11,14-tetrahydroxy-10-(hydroxymethyl)-13-methyl-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one	1802889: Na,K-ATPase Inhibition Assay from Article 10.1074/jbc.M114.557629: “Digoxin derivatives with enhanced selectivity for the a2 isoform of Na,K-ATPase: effects on intraocular pressure in rabbits.”	ki	0.0900	uM
(2R,4S,5R)-2-[[(3S,5R,8R,9S,10S,13R,14S,17S)-17-(aminomethyl)-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-6-methyloxane-3,4,5-triol;hydrochloride	56911: Inhibition of [3H]- ouabain binding to digitalis receptor	ic50	0.0990	uM
(2R,4bS,7S,8aR)-2-[(1E,3S)-1-[2-(dimethylamino)ethoxyimino]pentan-3-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1000	uM
(2R,4bS,7S,8aR)-2-[(2S,4E)-4-(2-aminoethoxyimino)butan-2-yl]-7-hydroxy-2,4b-dimethyl-4,4a,5,6,7,8,8a,9,10,10a-decahydro-3H-phenanthren-1-one	146843: Binding affinity towards Na+,K+ -ATPase isolated from dog kidney.	ic50	0.1000	uM
2-[(E)-[(3S,5R,8R,9S,10S,13R,14S,17S)-3,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]methylideneamino]guanidine;hydrochloride	146856: Displacement of [3H]ouabain from dog kidney Na+/K+ ATPase	ic50	0.1000	uM

CTD chemical–gene interactions

79 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	affects expression, decreases expression, increases expression	5
Acetaminophen	affects expression, decreases expression, increases expression	4
Valproic Acid	affects expression, increases expression, increases methylation	4
Cyclosporine	decreases expression	4
Arsenic Trioxide	decreases expression, decreases response to substance	3
Estradiol	increases expression, decreases expression, decreases reaction	3
Particulate Matter	decreases expression, affects cotreatment, affects expression, increases abundance	3
sodium arsenite	increases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
(+)-JQ1 compound	increases expression	2
Decitabine	affects cotreatment, affects expression, decreases expression, decreases reaction, increases methylation	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
Silicon Dioxide	decreases expression, increases expression	2
Smoke	decreases expression	2
Tobacco Smoke Pollution	affects expression, increases expression	2
methylmercuric chloride	increases expression	1
2-methyl-4-isothiazolin-3-one	increases expression	1
cobaltous chloride	increases expression	1
butyraldehyde	decreases expression	1
potassium bromate	decreases expression	1
perfluorooctanoic acid	decreases expression	1
ochratoxin A	decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, decreases expression	1
cupric chloride	increases expression	1
dibenzo(a,l)pyrene	increases expression	1
beta-methylcholine	affects expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
chromium hexavalent ion	affects expression	1
perfluorooctane sulfonic acid	decreases expression	1
tacedinaline	increases expression	1

ChEMBL screening assays

50 unique, capped per target: 50 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1691887	Binding	Inhibition of human Na+/ K+ ATPase at up to 10 uM	Lersivirine, a nonnucleoside reverse transcriptase inhibitor with activity against drug-resistant human immunodeficiency virus type 1. — Antimicrob Agents Chemother

Clinical trials (associated diseases)

265 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00146822	PHASE4	COMPLETED	REFLEx Study (ENDOTAK RELIANCE G Evaluation of Handling and Electrical Performance
NCT00187239	PHASE4	COMPLETED	Reduce Ventricular Pacing in Dual Chamber Implantable Cardioverter Defibrillators Using AutoIntrinsic Conduction Search Study
NCT00247533	PHASE4	UNKNOWN	Cerebral Artery Stenosis, Coronary Artery Disease and Arrhythmia
NCT00282620	PHASE4	UNKNOWN	Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient’s Quality of Life.
NCT00290056	PHASE4	UNKNOWN	Effect of Supplemental Intake of Omega-3 Polyunsaturated Fatty Acids on the Rate and Complexity of Spontaneously Occurring Ventricular and Supraventricular Arrhythmias in Patients With Implantable Cardioverter Defibrillator (ICD) - A Randomized Clinical Trial
NCT00313443	PHASE4	COMPLETED	Concentrations of Amiodarone in Fat Tissue During Chronic Treatment
NCT00457340	PHASE4	COMPLETED	Atorvastatin For The Reduction Of Ventricular Arrhythmias
NCT00507390	PHASE4	WITHDRAWN	Omega 3 Polyunsaturated Fatty Acid Supplements (PUFAs) and Microvolt T Wave Alternans (TWA) in Patients With Ventricular Arrhythmia
NCT00575523	PHASE4	COMPLETED	Atropine for Prevention of Dysrhythmias Caused by Percutaneous Ethanol Instillation for Hepatoma Therapy
NCT00579098	PHASE4	COMPLETED	The Use of Statins Following a Left Atrial Catheter Ablation Procedure to Prevent Atrial Fibrillation
NCT01613092	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01628666	PHASE4	COMPLETED	Prevention of Arrhythmia Device Infection Trial (PADIT)
NCT01717469	PHASE4	UNKNOWN	Safety and the Effects of Isolated Left Ventricular Pacing in Patients With Bradyarrhythmias
NCT01819064	PHASE4	COMPLETED	Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants
NCT01834872	PHASE4	UNKNOWN	Safety and Feasibility of Arrhythmia Ablation Using the Amigo Remote Robotic System as Compared With Manual Ablation
NCT01841242	PHASE4	COMPLETED	Comparison of Alcoholic Chlorhexidine 2% Versus Alcoholic Povidone Iodine for Infections Prevention With Cardiac Resynchronization Therapy Device Implantation
NCT01991223	PHASE4	UNKNOWN	Dexmedetomidine for Catheter-related Bladder Discomfort
NCT02045173	PHASE4	COMPLETED	Automate Detection of Sleep Apnea by ApneascanTM
NCT02203630	PHASE4	TERMINATED	Phenylephrine Versus Norepinephrine for Septic Shock in Critically Ill Patients
NCT02565069	PHASE4	COMPLETED	Identification for the Treatment of Complex Arrhythmias
NCT03273634	PHASE4	COMPLETED	The Effect of Proton Pump Inhibition on Palpitations
NCT03289429	PHASE4	UNKNOWN	Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery
NCT03895411	PHASE4	UNKNOWN	Efficacy and Safety of Sotalol in Children With Arrhythmia
NCT05486377	PHASE4	COMPLETED	Remimazolam vs Desflurane for General Anesthesia for Ablation of Arrhythmia
NCT06574555	PHASE4	COMPLETED	Norepinephrine ED90 Bolus After Spinal Anesthesia in Cesarean Section
NCT00000464	PHASE3	COMPLETED	Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (CASCADE)
NCT00000476	PHASE3	COMPLETED	Digitalis Investigation Group (DIG)
NCT00000480	PHASE3	COMPLETED	Multicenter Unsustained Tachycardia Trial (MUSTT)
NCT00000492	PHASE3	COMPLETED	Beta-Blocker Heart Attack Trial (BHAT)
NCT00000502	PHASE3	COMPLETED	Evaluation of SC-V Versus Conventional CPR
NCT00000517	PHASE3	COMPLETED	Boston Area Anticoagulation Trial for Atrial Fibrillation (BAATAF)
NCT00000518	PHASE3	COMPLETED	Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM)
NCT00000531	PHASE3	COMPLETED	Antiarrhythmics Versus Implantable Defibrillators (AVID)
NCT00000540	PHASE3	COMPLETED	Coronary Artery Bypass Graft (CABG) Patch Trial
NCT00000556	PHASE3	COMPLETED	Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM)
NCT00000561	PHASE3	COMPLETED	Mode Selection Trial in Sinus Node Dysfunction (MOST)
NCT00000609	PHASE3	COMPLETED	Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)
NCT00004559	PHASE3	COMPLETED	Fatty Acid Antiarrhythmia Trial (FAAT)
NCT00004560	PHASE3	COMPLETED	Public Access Defibrillation (PAD) Community Trial
NCT00035490	PHASE3	COMPLETED	Efficacy and Safety Evaluation of Azimilide Dihydrochloride in Patients With Implantable Cardioverter Defibrillators